David Kurtz
Affiliations: | 2013-2017 | Bioengineering | Stanford University, Palo Alto, CA |
Google:
"David Kurtz"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Tabari E, Lovejoy AF, Lin H, et al. (2024) NGS-determined molecular markers and disease burden metrics from ctDNA correlate with PFS in previously untreated DLBCL. Leukemia & Lymphoma. 1-11 |
| Alig SK, Esfahani MS, Garofalo A, et al. (2023) Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling. Nature |
| Sworder BJ, Kurtz DM. (2023) Cell-free DNA in large B-cell lymphoma: MRD and beyond. Seminars in Hematology |
| Esfahani MS, Hamilton EG, Mehrmohamadi M, et al. (2022) Inferring gene expression from cell-free DNA fragmentation profiles. Nature Biotechnology |
| Roschewski M, Rossi D, Kurtz DM, et al. (2021) Circulating Tumor DNA in Lymphoma: Principles and Future Directions. Blood Cancer Discovery. 3: 5-15 |
| Shah AT, Azad TD, Breese MR, et al. (2021) A comprehensive circulating tumor DNA assay for detection of translocation and copy number changes in pediatric sarcomas. Molecular Cancer Therapeutics |
| Kurtz DM, Soo J, Co Ting Keh L, et al. (2021) Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nature Biotechnology |
| Alig S, Macaulay CW, Kurtz DM, et al. (2021) Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2002573 |
| Kurtz DM. (2021) Bringing circulating tumor DNA to the clinic in Hodgkin lymphoma. Haematologica. 106: 5-6 |
| Avanzini S, Kurtz DM, Chabon JJ, et al. (2020) A mathematical model of ctDNA shedding predicts tumor detection size. Science Advances. 6 |